IDT Australia Limited (AU:IDT)
ASX:IDT
Top Page
IDT Australia Limited
(Sydney:IDT)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.04
▼(-20.00% Downside)
Action:ReiteratedDate:02/19/26
The score is primarily held back by weak financial performance, including ongoing losses and negative operating/free cash flow. Technical signals are mixed with neutral momentum but a weaker longer-term trend, while valuation is also pressured due to loss-making earnings and no dividend support.
Positive Factors
CDMO business model
IDT's fee-for-service CDMO model sells development, manufacturing and supply-chain services to pharmaceutical clients. Structural industry outsourcing supports multi-year demand and contract stickiness; predictable project pipelines can sustain utilization-driven revenue stability if capacity stays deployed.
Negative Factors
Negative operating and free cash flow
Sustained negative operating and free cash flows erode liquidity and constrain reinvestment in capacity or compliance. Over a multi-month horizon this increases reliance on external funding or covenant headroom, limiting strategic flexibility and amplifying risk if project timing or collections slip.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO business model
IDT's fee-for-service CDMO model sells development, manufacturing and supply-chain services to pharmaceutical clients. Structural industry outsourcing supports multi-year demand and contract stickiness; predictable project pipelines can sustain utilization-driven revenue stability if capacity stays deployed.
Read all positive factors
IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$18.51M
Dividend YieldN/A
Average Volume (3M)336.94K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth45.30%
EPS Growth-24.18%
CountryAU
Employees156
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding427,425,570
10 Day Avg. Volume373,970
30 Day Avg. Volume336,941
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)1.73
Price to Sales (P/S)1.92
P/FCF Ratio-5.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDT Australia Limited Business Overview & Revenue Model
Company Description
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability cham...
How the Company Makes Money
IDT primarily makes money by providing fee-for-service pharmaceutical contract development and manufacturing (CDMO) work. Key revenue streams include: (1) manufacturing services, where customers pay IDT to produce drug products (including sterile ...
IDT Australia Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.00M | 19.77M | 13.23M | 6.93M | 12.11M | 15.99M |
| Gross Profit | 7.10M | 9.69M | 10.42M | -3.53M | 2.82M | 4.88M |
| EBITDA | -4.11M | -6.54M | -5.56M | -8.83M | -340.00K | 2.75M |
| Net Income | -6.13M | -8.06M | -5.41M | -8.50M | -1.16M | 2.10M |
Balance Sheet | ||||||
| Total Assets | 34.55M | 36.92M | 31.37M | 28.29M | 30.08M | 34.13M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 4.11M | 904.00K | 4.43M | 9.21M | 6.93M |
| Total Debt | 9.86M | 10.40M | 4.47M | 740.00K | 881.00K | 766.00K |
| Total Liabilities | 14.23M | 15.03M | 7.93M | 4.15M | 3.46M | 6.51M |
| Stockholders Equity | 20.31M | 21.89M | 23.44M | 24.14M | 26.63M | 27.61M |
Cash Flow | ||||||
| Free Cash Flow | -885.00K | -7.55M | -10.30M | -8.42M | 1.95M | -156.00K |
| Operating Cash Flow | 609.00K | -6.25M | -9.60M | -7.90M | 2.86M | 370.00K |
| Investing Cash Flow | -3.19M | -4.50M | -1.09M | -522.00K | -912.00K | -526.00K |
| Financing Cash Flow | 3.46M | 10.75M | 6.77M | 3.64M | 337.00K | 224.00K |
IDT Australia Limited Technical Analysis
Neutral
0.05
Price Trends
0.05
Negative
0.05
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
28.80
Positive
-16.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Neutral. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 28.80 is Positive, neither overbought nor oversold. The STOCH value of -16.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IDT.
IDT Australia Limited Peers Comparison
UnderperformOutperform
Sector (51)
AU:IDT
IDT Australia Limited
0.05
-0.06
-57.14%
AU:LGP
Little Green Pharma Ltd.
0.10
-0.02
-19.17%
AU:MVP
Medical Developments International Limited
0.43
-0.04
-7.61%
AU:VIT
Cronos Australia Ltd.
0.04
-0.03
-40.00%
IDT Australia Limited Corporate Events
IDT Australia Director Increases Indirect Shareholding via On-Market Trades
Mar 26, 2026
IDT Australia director Mark Simari has increased his indirect shareholding in the company through entities Charkaroo Pty Ltd and Jodmar Pty Ltd, which collectively acquired 325,000 fully paid ordinary shares in on-market trades. The purchases, exe...
IDT Australia Tightens Governance with Revised Security Trading Policy
Mar 26, 2026
IDT Australia Limited has updated its Security Trading Policy in line with ASX Listing Rule 12.10, reflecting the company’s ongoing focus on regulatory compliance and governance standards in its role as a specialist contract pharmaceutical m...
IDT Australia Director Increases Indirect Shareholding via On-Market Purchase
Feb 23, 2026
IDT Australia has disclosed a change in director Mark Simari’s interests, with an indirect on-market purchase of 501,936 ordinary fully paid shares at $0.048 per share. The transaction, executed via entities Charkaroo Pty Ltd and Jodmar Pty ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.